⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22991201 | 0.89 | CHRNB2 (0.56) | — | |
| SCHEMBL1971629 | 0.82 | CHRNB2 (0.54) | — | |
| SCHEMBL14193291 | 0.82 | CHRNB2 (0.54) | — | |
| SCHEMBL21339455 | 0.81 | CHRNB2 (0.48) | — | |
| SCHEMBL21339452 | 0.81 | CHRNB2 (0.48) | — | |
| SCHEMBL20207288 | 0.81 | CHRNB2 (0.48) | — | |
| SCHEMBL21339145 | 0.81 | CHRNB2 (0.48) | — | |
| SCHEMBL50397 | 0.79 | — | — | |
| SCHEMBL524422 | 0.79 | — | — | |
| SCHEMBL4513056 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746414-B | Aza-quinoline compounds and uses thereof | 诺华公司 | 2024-10-18 | — | — | CN | claimed |
| CN-114585619-B | Alpha-D-galactopyranoside derivatives | 爱杜西亚药品有限公司 | 2024-09-27 | — | — | CN | claimed |
| US-12012409-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-06-18 | — | — | US | claimed |
| EP-4034535-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2022-08-03 | — | — | EP | claimed |
| CN-114746414-A | Aza-quinoline compounds and uses thereof | 诺华公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114585619-A | alpha-D-galactopyranoside derivatives | 爱杜西亚药品有限公司 | 2022-06-03 | — | — | CN | claimed |
| WO-2021146424-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-07-22 | — | — | WO | claimed |
| US-20210214366-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-07-15 | — | — | US | claimed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2015119712-A1 | TETRACYCLIC CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2015-08-13 | — | — | WO | claimed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-5286721-A | Antimicrobial agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-02-15 | — | — | US | claimed |
| WO-1992006978-A1 | 1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-30 | — | — | WO | claimed |
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-1996036602-A1 | ADNAZ, COMPOSITIONS AND PROCESSES | THE UNITED STATES OF AMERICA (US) | 1996-11-21 | — | — | WO | disclosed |
| US-5286721-A | Antimicrobial agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-02-15 | — | — | US | disclosed |
| US-5130309-A | Cardiovascular disorders | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-07-14 | — | — | US | disclosed |
| WO-1992006978-A1 | 1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-30 | — | — | WO | disclosed |